Adenovirus-Vectored Drug-Vaccine Duo as a Rapid-Response Tool for Conferring Seamless Protection against Influenza 英文参考文献.docVIP

Adenovirus-VectoredDrug-VaccineDuoasaRapid- ResponseToolforConferringSeamlessProtection againstInfluenza JianfengZhang1,E.BartTarbet2,TsungweiFeng1,ZhongkaiShi1,KentR.VanKampen1,De-chuC. Tang1* 1Vaxin,Inc.,Birmingham,Alabama,UnitedStatesofAmerica,2InstituteforAntiviralResearch,UtahStateUniversity,Logan,Utah,UnitedStatesofAmerica Abstract Fewotherdiseasesexertsuchahugetollofsufferingasinfluenza.Wereportherethatintranasal(i.n.)administrationofE1/ E3-defective (DE1E3) adenovirus serotype 5 (Ad5) particles rapidly induced an anti-influenza state as a means of prophylactictherapy whichpersistedfor severalweeksin mice.By encodinganinfluenza virus(IFV)hemagglutinin(HA) HA1 domain, an Ad5-HA1 vector conferred rapid protection as a prophylactic drug followed by elicitation of sustained protectiveimmunityasavaccineforinducingseamlessprotectionagainstinfluenzaasadrug-vaccineduo(DVD)inasingle package.SinceAd5particlesinduceacomplexwebofhostresponses,whichcouldarrestinfluenzabyactivatingaspecific armofinnateimmunitytoimpedeIFVgrowthintheairway,itisconceivablethatthismulti-prongedinfluenzaDVDmay escapethefateofdrugresistancethatimpairsthecurrentinfluenzadrugs. Citation: Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, et al. (2011) Adenovirus-Vectored Drug-Vaccine Duo as a Rapid-Response Tool for Conferring SeamlessProtectionagainstInfluenza.PLoSONE6(7):e22605.doi:10.1371/journal.pone.0022605 Editor:K.T.Jeang,NationalInstituteofHealth,UnitedStatesofAmerica ReceivedMay19,2011;AcceptedJune25,2011;PublishedJuly27,2011 Copyright: ? 2011 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited. Funding:ThisworkwassupportedbyNationalInstitutesofHealthgrants2-R44-AI-068285-02and1-UC1-AI-067198-01;aNationalInstitutesofHealthcontract N01-AI-30063; and a National Institute of Allergy and Infectious Diseases Non